Today’s Stock Alert: Could Delcath Systems, Inc. Crash Even More? The Stock Just Made 52-Week Low

Today's Stock Alert: Could Delcath Systems, Inc. Crash Even More? The Stock Just Made 52 Week Low

The stock of Delcath Systems, Inc. (NASDAQ:DCTH) hit a new 52-week low and has $2.25 target or 13.00% below today’s $2.59 share price. The 9 months bearish chart indicates high risk for the $3.80 million company. The 1-year low was reported on Sep, 30 by If the $2.25 price target is reached, the company will be worth $494,000 less.
The 52-week low event is an important milestone for every stock because it shows very negative momentum and is time when sellers come in. During such technical setups, fundamental investors usually stay away and are careful buying the stock. About 279,534 shares traded hands or 1970.01% up from the average. Delcath Systems, Inc. (NASDAQ:DCTH) has declined 20.14% since February 26, 2016 and is downtrending. It has underperformed by 30.56% the S&P500.

Analysts await Delcath Systems, Inc. (NASDAQ:DCTH) to report earnings on November, 8.

According to Zacks Investment Research, “Delcath Systems, Inc. has developed a system, the Delcath system, to isolate the liver from the general circulatory system and to administer chemotherapy and other therapeutic agents directly to the liver.”

Insitutional Activity: The institutional sentiment decreased to 1.13 in Q2 2016. Its down 0.30, from 1.43 in 2016Q1. The ratio dropped, as 7 funds sold all Delcath Systems, Inc. shares owned while 1 reduced positions. 2 funds bought stakes while 7 increased positions. They now own 1.85 million shares or 18.13% less from 2.26 million shares in 2016Q1.
Royal Natl Bank Of Canada has 2,563 shares for 0% of their US portfolio. Private Advisor Grp Llc holds 0% of its portfolio in Delcath Systems, Inc. (NASDAQ:DCTH) for 206,670 shares. Grp Inc One Trading L P, a Illinois-based fund reported 5,123 shares. Geode Mngmt Limited Liability Company reported 39,792 shares or 0% of all its holdings. Barclays Plc has 15 shares for 0% of their US portfolio. Goldman Sachs has 15,211 shares for 0% of their US portfolio. Susquehanna Ltd Liability Partnership holds 0% of its portfolio in Delcath Systems, Inc. (NASDAQ:DCTH) for 39,047 shares. Creative Planning reported 307 shares or 0% of all its holdings. Blackrock Fund Advisors owns 4,024 shares or 0% of their US portfolio. The North Carolina-based Bank Of America De has invested 0% in Delcath Systems, Inc. (NASDAQ:DCTH). Blackrock Institutional Trust Na, a California-based fund reported 531,871 shares. Vanguard Group Inc Incorporated last reported 77,988 shares in the company. The New York-based Renaissance Tech Lc has invested 0% in Delcath Systems, Inc. (NASDAQ:DCTH). Citadel Advsr holds 0% or 157,333 shares in its portfolio. Wells Fargo And Mn accumulated 157 shares or 0% of the stock.

More notable recent Delcath Systems, Inc. (NASDAQ:DCTH) news were published by: which released: “Delcath Announces Proposed Public Offering of Common Stock and Warrants” on September 29, 2016, also with their article: “Delcath Systems Inc.” published on December 22, 2009, published: “Mid-Morning Market Update: Markets Open Higher; McCormick Profit Tops Estimates” on September 30, 2016. More interesting news about Delcath Systems, Inc. (NASDAQ:DCTH) were released by: and their article: “Delcath prices stock offering at $3; shares off 21%” published on September 30, 2016 as well as‘s news article titled: “Stocks Hitting 52-Week Lows” with publication date: September 30, 2016.

DCTH Company Profile

Delcath Systems, Inc., incorporated on August 5, 1988, is a late-stage clinical development firm with early commercial activity in Europe focused on cancers of the liver. The Firm is a specialty pharmaceutical and medical device firm developing its product, Melphalan Hydrochloride for Injection for use with the Delcath Hepatic Delivery System (Melphalan/HDS). The Company’s system delivers and filters melphalan hydrochloride, which is marketed as a device under the trade name Delcath Hepatic CHEMOSAT Delivery System for Melphalan (CHEMOSAT). The Company’s focus is on the execution of the clinical development program (CDP) in ocular melanoma liver metastases (mOM), intrahepatic cholangiocarncinoma (ICC), hepatocellular carcinoma (HCC or primary liver) and other cancers that are metastatic to the liver.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Tags: , ,

Leave a Comment